Leveraging a Flexible Resourcing Model to Achieve Study Success
Fluctuating resourcing demand has been a challenge for the broader clinical research industry since the beginning of time. Only recently has the demand for flexible and innovative solutions to address these challenges become more pressing.
Recent studies reveal that out of the more than 5,000 clinical trials that were stopped between December of 2019 and January of 2021, 36% reported suspended, terminated, or withdrawn for reasons that explicitly cite COVID-19.
The launch of the COVID-19 vaccine brings us a glimmer of hope for recovery in the clinical trials space as travel bans are lifted and sites begin to reopen. But how will CROs and sponsors alike recover from the bolus of work collected over the past year?
Tune into our Arena-hosted webinar where Vice President, Catalyst Flex Growth Strategy, Betsy Brown, and Senior Vice President, Resourcing Operations, Kathy Bradrick discuss with guest speaker, Maggie Neptune key outsourced staffing strategies needed by mid-tier biopharma and life sciences companies to achieve study success before, during and in the wake of the pandemic while gaining a sponsor’s perspective on the benefits of a flexible resourcing model.
Presented by
Betsy Brown,
Vice president, Catalyst Flex Growth Strategy
Betsy has dedicated her entire career to clinical research and serves today as an industry leader, resourcing expert and business entrepreneur. She first joined the industry in 1985 working with FHI 360 in Women’s Health and HIV research. In 1987, she joined ClinTrials Research, a commercial spin-off of FHI 360 and one of the earliest international Clinical Research Organizations. As Associate Director, she managed a staff of CRA Managers and more than 100 CRAs. In 1995, Betsy co-founded and led The Woolf Group, one of the earliest and most recognized clinical research staffing firms in the country. She helped develop the company into a premier service organization, highly sought-after by its clientele and candidates alike. The company was sold to an international staffing firm in 1999, and in 2002 she co-founded Trio Clinical Research. As the company’s Chief Operating Officer and then President, Betsy led the operations and business development team, ensuring the company’s growth and development and drove a successful merger with Aptiv Solutions in 2008. In 2013, Betsy returned to her entrepreneurial roots and co-founded Catalyst Clinical Research, a niche clinical operations service provider.
Kathy Bradrick,
Senior Vice President of Resourcing Operations
Kathy Bradrick, Senior Vice President of Resourcing Operations at Catalyst Clinical Research, is a clinical research executive and leader with more than 25 years’ experience in large and small CROs, as well as pharmaceutical and government research companies. She started her career as a pharmaceutical sales rep in 1989 and entered the CRO industry in 1997. Kathy has served in a variety of leadership roles throughout her career, including President of Trio Clinical Research; Co-Founder and Managing Partner of INNO Clinical Outcomes; Executive Director of Source at Chiltern International; Executive Director of Business Operations at Triangle Biostatistics (now part of Catalyst); as well as Vice President of Growth Strategy and now Senior Vice President of Resourcing at Catalyst Clinical Research. Kathy holds a bachelor’s degree in economics from the University of Illinois and a master’s degree in management from North Carolina State University.
Maggie Neptune,
Clinical Strategy and Operations consultant
Maggie Neptune is a Clinical Strategy and Operations consultant with more than 30 years’ experience. Although she has worked with large pharmaceutical companies including Johnson & Johnson, Fujifilm Pharmaceuticals, Maggie’s passion is helping start-up biotech companies to reach proof-of-concept by utilizing creative, cost-effective and time-sensitive processes. During the COVID-19 pandemic, Maggie provided oversight of the initial trials of a potential COVID-19 treatment while planning and executing the Phase 1 and POC studies for 2 new biotech companies in the imaging space. Prior to starting her consulting business, Maggie served as Vice-president of Clinical Operations at FerroKin BioSciences, successfully sold to Shire Pharma following POC of its lead compound. As a Senior Director, she oversaw the Genentech Phase IV and label expansion programs for Rituxan. Maggie started her career as a study coordinator at Memorial Sloan-Kettering Cancer Center, running NCI-funded multidisciplinary trials in lung and esophageal cancer. She has successfully run numerous global clinical trials, from large Phase 3 studies to unique Phase 1 programs in orphan diseases. She has worked directly with academic centers, small specialty clinics and evolving health care centers in North and South America, Australia, Europe and Asia. She has managed large CROs and built consortiums of smaller vendors when it best suited the drug development plan. Maggie received her B.S. from UCLA in Physics and Biomechanics.
